Emalex eyes FDA approval for Tourette syndrome therapy after Phase III success
The Phase III DIAMOND trial met both its primary and secondary endpoints of reducing tics in both children and adult patients ...
BioSpace5h
Emalex Heads to FDA After Phase III Tourette Syndrome Win
In the Phase III trial, 41.9% of pediatric Tourette syndrome patients relapsed after ecopipam treatment, as compared with ...
Crain's Chicago Business3h
Chicago pharma gets good news on Tourette syndrome drug candidate
Ecopipam showed statistical significance in treating Tourette syndrome versus a placebo for both its primary efficacy ...
Medpage Today on MSN5h
'Banned' Words at CDC? House Passes Budget Bill; Measles Outbreak in Texas Expands
CDC staff received an email this week telling them to avoid using more than a dozen terms or words -- including "health ...
ENDPOINTS NEWS23h
Chica­go biotech Emalex says it cleared a Phase 3 for Tourette syn­drome, will seek FDA ap­proval
Emalex Biosciences said its daily oral tablet helped reduce relapses for children and adults with Tourette syndrome in a ...
pharmaphorum19h
Asarina folds as it ends search for Tourette's drug partner
At the moment, attention is focused on candidates like Emalex Biosciences' ecopipam and Noema Pharma's gemlapodect, both in midstage clinical testing. An extraordinary meeting of shareholders is ...
The Pharma Letter4h
Ligand invests $75 million in Castle Creek’s gene therapy
Ligand Pharmaceuticals (Nasdaq: LGND) has entered into a royalty financing agreement with Castle Creek Biosciences, providing ...